Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03049111 · ClinicalTrials.gov registry record · Early Phase 1
Screening Inhaled Allergen Challenge for Dermatophagoides Farinae
A Early Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT03049111: Clinical Trial Early Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
NCT03049111 is a Early Phase 1 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 14 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03049111, a Early Phase 1 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study is designed to identify Dermatophagoides farinae, or Der f, sensitive asthmatics who demonstrate a late phase asthmatic response after Der f inhalation. These subjects may be invited to participate in a planned future study investigating novel asthma treatments.
Primary Outcome
Participants will undergo an inhaled allergen challenge to identify those with a measurable late phase response (LPR) to inhaled house dust mite allergen. Pre-challenge FEV1 will be measured prior to administration of the allergen challenge. The presence of an LPR will be defined as a decline in FEV1 of ≥10% from pre-challenge values 3-10 hours post-challenge.
Interventions
- BIOLOGICAL Der f
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-01-29 |
| Est. Completion | 2019-10-03 |
| Phase | Early Phase 1 |
Why NCT03049111 stopped before completion
NCT03049111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Der f is the first listed.
NCT03049111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03049111 about?
NCT03049111 is a clinical study titled "Screening Inhaled Allergen Challenge for Dermatophagoides Farinae". This study is designed to identify Dermatophagoides farinae, or Der f, sensitive asthmatics who demonstrate a late phase asthmatic response after Der f inhalation. These subjects may be invited to participate in a planned future study investigating novel asthma treatments.
What is the current status of trial NCT03049111?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2018-01-29. Estimated completion is 2019-10-03.
What interventions are being tested in trial NCT03049111?
The interventions under investigation include: Der f (BIOLOGICAL).
Who is sponsoring clinical trial NCT03049111?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03049111's enrollment target sits among peer trials
14 1474th of 2000 higher than 498 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy